Meridian Bioscience (VIVO) Stock Price
Meridian Bioscience Price
Over the last 19 years Meridian Bioscience grew revenue by 8.9% annually, reaching 333.02 M USD. Earnings per share have grown at 8.4% per year over the last 19 years. For Meridian Bioscience, the net margin of 12.7% is up versus 11.1% a few years ago. At today's price the dividend yield works out to roughly 2.98%. The payout ratio is around 22% of earnings. The stock trades about 247% above its 52-week low.
Meridian Bioscience stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Meridian Bioscience over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Meridian Bioscience stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Meridian Bioscience's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Meridian Bioscience Price |
|---|---|
| 9/8/2026 | 4.20 USD |
| 9/4/2026 | 3.89 USD |
| 9/3/2026 | 3.92 USD |
| 9/2/2026 | 3.78 USD |
| 9/1/2026 | 3.81 USD |
| 8/31/2026 | 4.07 USD |
| 8/28/2026 | 4.06 USD |
| 8/27/2026 | 4.28 USD |
| 8/26/2026 | 4.20 USD |
| 8/25/2026 | 4.17 USD |
| 8/24/2026 | 4.19 USD |
| 8/21/2026 | 4.36 USD |
| 8/20/2026 | 4.21 USD |
| 8/19/2026 | 4.34 USD |
| 8/18/2026 | 4.52 USD |
| 8/14/2026 | 4.87 USD |
| 8/13/2026 | 4.59 USD |
| 8/12/2026 | 4.08 USD |
| 8/10/2026 | 3.99 USD |
| 8/7/2026 | 4.04 USD |
| 8/6/2026 | 3.83 USD |
| 8/5/2026 | 3.79 USD |
| 8/4/2026 | 3.83 USD |
| 8/3/2026 | 3.73 USD |
| 7/31/2026 | 3.57 USD |
| 7/30/2026 | 3.54 USD |
| 7/29/2026 | 3.71 USD |
| 7/27/2026 | 3.87 USD |
| 7/23/2026 | 3.91 USD |
| 7/22/2026 | 3.90 USD |
Meridian Bioscience Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Meridian Bioscience Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 143.00 | 158.00 | 172.00 | 188.00 | 188.00 | 194.00 | 196.00 | 200.00 | 213.00 | 201.00 | 253.00 | 317.00 | 333.00 | 294.00 | 302.00 | 300.00 |
| -3.38 | 10.49 | 8.86 | 9.30 | – | 3.19 | 1.03 | 2.04 | 6.50 | -5.63 | 25.87 | 25.30 | 5.05 | -11.71 | 2.72 | -0.66 |
| 61.54 | 62.03 | 63.37 | 64.36 | 62.23 | 62.37 | 64.80 | 62.00 | 61.50 | 58.71 | 61.66 | 63.41 | 56.46 | 56.46 | 56.46 | 56.46 |
| 88.00 | 98.00 | 109.00 | 121.00 | 117.00 | 121.00 | 127.00 | 124.00 | 131.00 | 118.00 | 156.00 | 201.00 | 188.00 | 165.98 | 170.50 | 169.37 |
| 41.00 | 41.00 | 50.00 | 57.00 | 52.00 | 56.00 | 53.00 | 44.00 | 44.00 | 38.00 | 68.00 | 101.00 | 75.00 | 46.00 | 32.00 | 22.00 |
| 28.67 | 25.95 | 29.07 | 30.32 | 27.66 | 28.87 | 27.04 | 22.00 | 20.66 | 18.91 | 26.88 | 31.86 | 22.52 | 15.65 | 10.60 | 7.33 |
| 26.00 | 26.00 | 33.00 | 38.00 | 34.00 | 35.00 | 32.00 | 21.00 | 23.00 | 24.00 | 46.00 | 71.00 | 42.00 | 37.00 | 26.00 | 18.00 |
| -18.75 | – | 26.92 | 15.15 | -10.53 | 2.94 | -8.57 | -34.38 | 9.52 | 4.35 | 91.67 | 54.35 | -40.85 | -11.90 | -29.73 | -30.77 |
| 41.10 | 41.40 | 41.60 | 41.90 | 41.90 | 42.00 | 42.40 | 42.60 | 42.80 | 42.90 | 43.20 | 44.01 | 44.38 | 44.38 | 44.38 | 44.38 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Meridian Bioscience generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Meridian Bioscience retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Meridian Bioscience's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Meridian Bioscience has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Meridian Bioscience's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Meridian Bioscience stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Meridian Bioscience Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Meridian Bioscience business model & stock analysis
Meridian Bioscience SWOT Analysis
Strengths
Meridian Bioscience Inc has a strong reputation in the healthcare industry, particularly in the field of diagnostics and testing kits. The company's advanced technology and extensive product portfolio give it a competitive edge.
Meridian Bioscience Inc has a solid financial position with stable revenues and profits. Its strong financial standing allows the company to invest in research and development, innovate its product offerings, and expand its market presence.
Weaknesses
Despite its strong reputation and financial position, Meridian Bioscience Inc faces certain weaknesses. The company relies heavily on a few key customers for a significant portion of its revenue, which creates a dependency and increases the risk of revenue fluctuations.
Another weakness is the limited geographical presence of Meridian Bioscience Inc. The company primarily operates within the United States, which restricts its market reach and exposes it to potential risks associated with regional economic downturns or regulatory changes.
Opportunities
The increasing global demand for diagnostics and healthcare products presents significant opportunities for Meridian Bioscience Inc. The company can expand its market presence by entering new geographical regions and tapping into emerging markets with a growing need for healthcare solutions.
Furthermore, advancements in technology and the ongoing COVID-19 pandemic have accelerated the importance of rapid testing and diagnostics. Meridian Bioscience Inc can leverage these opportunities to develop and market innovative solutions that address the evolving healthcare landscape.
Threats
Meridian Bioscience Inc faces competition from other established players in the healthcare industry. The presence of larger competitors with greater resources and market presence poses a threat to the company's market share and growth prospects.
Additionally, regulatory challenges and changing government policies can create uncertainties for Meridian Bioscience Inc. Compliance with evolving regulations and adherence to quality standards require continuous monitoring and can impact the company's operations and profitability.
Meridian Bioscience Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Meridian Bioscience historical P/E ratio, EBIT multiple, and P/S ratio
Meridian Bioscience annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Meridian Bioscience shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Meridian Bioscience stock splits
Meridian Bioscience Dividend History
20 years of dividend payments
Meridian Bioscience dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Meridian Bioscience Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/20/2023 | 0.21USD | - | 74.59 MUSD | - | 2023 Q4 |
| 8/3/2023 | 0.21USD | - | 77.95 MUSD | - | 2023 Q3 |
| 5/4/2023 | 0.22USD | - | 76.33 MUSD | - | 2023 Q2 |
| 2/2/2023 | 0.20USD | - | 72.52 MUSD | - | 2023 Q1 |
| 11/29/2022 | 0.15USD | - | 68.44 MUSD | - | 2022 Q4 |
| 8/5/2022 | 0.16USD | - | 67.82 MUSD | - | 2022 Q3 |
| 5/6/2022 | 0.48USD | - | 101.03 MUSD | - | 2022 Q2 |
| 2/4/2022 | 0.26USD | - | 71.35 MUSD | - | 2022 Q1 |
| 11/12/2021 | 0.21USD | - | 69.42 MUSD | - | 2021 Q4 |
| 8/6/2021 | 0.31USD | - | 78.38 MUSD | - | 2021 Q3 |
Meridian Bioscience shareholder structure
| % | Name |
|---|---|
4.96770% | |
4.30630% | |
0.39246% | |
0.30378% | |
0.27342% | |
0.15851% |
Meridian Bioscience Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
27.20% | SEC ↗ | |
17.00% | SEC ↗ | |
11.21% | SEC ↗ | |
8.33% | SEC ↗ | |
8.33% | SEC ↗ | |
8.33% | SEC ↗ | |
8.11% | SEC ↗ | |
7.64% | SEC ↗ | |
7.50% | SEC ↗ | |
6.43% | SEC ↗ |
Meridian Bioscience Executives and Management Board
6 members · avg. age 53 · 33 % women
Mr. John Kenny (54)
Chief Executive Officer, Director · since 2017
4.60 M USD
Dr. Lourdes Weltzien (57)
Executive Vice President - Life Science
Mr. Tony Serafini - Lamanna (59)
Executive Vice President - Diagnostics
Mr. Andrew Kitzmiller (43)
Chief Financial Officer, Executive Vice President, Director · since 2022
Ms. Julie Smith (54)
Senior Vice President, Principal Accounting Officer, Controller
Mr. Charlie Wood
Vice President - Investor Relations · since 2021
Meridian Bioscience Supply Chain
Meridian Bioscience Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.78 | -0.77 | -0.47 | ||
| 2 | -0.86 | -0.68 | -0.26 | ||
| 3 | -0.78 | -0.74 | 0.09 |
Frequently asked questions about Meridian Bioscience
The business model of Meridian Bioscience Inc revolves around manufacturing and distributing diagnostic products for the healthcare industry. With a focus on infectious disease testing, the company provides a range of products including molecular and immunoassay tests, as well as reagents and related equipment. Meridian Bioscience Inc aims to develop innovative solutions for quick and accurate diagnosis, helping healthcare professionals worldwide make informed decisions. Through its expertise and continual investment in research and development, the company strives to improve patient outcomes and contribute to the overall public health. Meridian Bioscience Inc's commitment to quality and customer satisfaction is evident in their comprehensive portfolio of diagnostic solutions.
Meridian Bioscience Inc is primarily active in the healthcare and life sciences industries.
The main competitors of Meridian Bioscience Inc in the market are companies like Thermo Fisher Scientific, BD (Becton, Dickinson and Company), Quidel Corporation, and Bio-Rad Laboratories. These companies operate in the healthcare and diagnostics industry, offering similar products and services. Meridian Bioscience Inc competes based on factors such as product quality, technological advancements, pricing strategy, and customer satisfaction. While Thermo Fisher Scientific is a well-established player in the market, Meridian Bioscience Inc continues to carve its niche through innovative solutions and a strong customer-centric approach.
Meridian Bioscience Inc is a leading life science company that develops and markets a broad range of innovative diagnostic products. Founded in 1976, the company has a rich history and a strong background in developing and commercializing diagnostic tests for various infectious diseases. Meridian Bioscience Inc has evolved over the years and has expanded its product portfolio to cater to the needs of laboratories, hospitals, and other healthcare providers worldwide. With a focus on quality, accuracy, and reliability, the company has garnered a reputation for delivering efficient and effective diagnostic solutions. Meridian Bioscience Inc remains committed to advancing healthcare and improving patient outcomes through its cutting-edge diagnostic technologies and dedication to innovation.
Meridian Bioscience Inc has achieved several significant milestones throughout its history. One notable accomplishment is the company's development and commercialization of innovative diagnostic test kits for various diseases and healthcare conditions. Furthermore, Meridian Bioscience Inc has consistently expanded its product portfolio, introducing novel technologies to improve healthcare outcomes. The company's dedication to research and development has led to the successful launch of multiple FDA-cleared and CE-marked diagnostic tests. Meridian Bioscience Inc's commitment to quality has enabled it to establish a strong presence in the global diagnostics market.
Meridian Bioscience Inc is primarily present in the United States.
Meridian Bioscience Inc represents a strong set of values and corporate philosophy. The company is committed to quality and innovation in the field of biotechnology. They strive to provide accurate and reliable diagnostic solutions to improve patient care. Meridian Bioscience Inc also prioritizes integrity and ethical conduct in all aspects of their business operations. With a focus on customer satisfaction, they aim to exceed expectations and deliver exceptional products and services. As an industry leader, Meridian Bioscience Inc continues to drive advancements in the healthcare sector through their dedication to excellence and integrity.
6 analysts currently rate the Meridian Bioscience stock: 0 recommend buying, 3 holding and 3 selling.
Converted at the current exchange rate, the Meridian Bioscience share trades at 3.61 EUR (4.20 USD).
The Meridian Bioscience share (VIVO) is listed on 4 stock exchanges, including: NASDAQ (VIVO), Frankfurt (MR4.F), München (MR4.MU), London (0K0K.L).
Meridian Bioscience Inc is a global company specializing in the development, manufacture, and distribution of diagnostic and testing systems for the rapid and accurate identification of infectious diseases. The company was founded in 1976 and is headquartered in Cincinnati, Ohio. Meridian Bioscience operates several business segments, including diagnostics, OEM, and life science. In the diagnostics segment, the company offers a variety of products for the identification of infectious diseases, including tests for respiratory infections, gastroenteritis, STDs, and Zika virus. Meridian Bioscience's diagnostic products are used in clinical laboratories, hospitals, medical practices, and research laboratories worldwide. The OEM segment of Meridian Bioscience offers customized diagnostic products tailored to the specific requirements of OEM customers. This includes both raw materials and finished products that can be integrated into customers' diagnostic products. The OEM segment of Meridian Bioscience works closely with OEM customers to provide customized, cost-effective, and high-quality products. In the life science segment, Meridian Bioscience offers a wide range of products, including enzymes, antibodies, proteins, buffering solutions, and labeling reagents. These products are used in research and development, diagnostics, and industry. Meridian Bioscience has experienced strong growth in recent years, driven by the introduction of new products, expansion into new markets, and the acquisition of other companies. An example of this is the acquisition of the Bioline Group in 2018, a leading provider of molecular biology products used in research and diagnostics. Meridian Bioscience is committed to developing and manufacturing high-quality products that deliver fast and accurate results. The company works closely with customers and partners to develop innovative products that meet the needs of the healthcare industry. With its wide range of products and commitment to innovation and quality, Meridian Bioscience will continue to play an important role in the diagnostics industry.
The revenue cannot currently be calculated for Meridian Bioscience.
The profit cannot currently be calculated for Meridian Bioscience.
The P/E ratio cannot be calculated for Meridian Bioscience at the moment.
The P/S cannot be calculated for Meridian Bioscience currently.
The Eulerpool Quality Score for Meridian Bioscience is 6/10.
The ISIN of Meridian Bioscience is US5895841014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Meridian Bioscience is 871583. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Meridian Bioscience is VIVO. The ticker symbol is used to trade Meridian Bioscience shares on the stock exchange.
The current dividend yield of Meridian Bioscience is 2.98 %.
Meridian Bioscience pays a dividend, distributed in the months of , , , .
Meridian Bioscience paid dividends every year for the past 0 years.
Meridian Bioscience is assigned to the 'Health' sector.
To receive the latest dividend of Meridian Bioscience from amounting to 0.13 USD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
The dividends of Meridian Bioscience are distributed in USD.
Meridian Bioscience stock
Meridian Bioscience Peer Group
Meridian Bioscience Ticker
Meridian Bioscience FIGI
All fundamentals and in-depth analysis of Meridian Bioscience
Our stock analysis for Meridian Bioscience stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Meridian Bioscience. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.